CHEMOTHERAPY EXAM REVIEW
QUESTIONS WITH ACCURATE SOLUTIONS
2026
▶ Managing Non-DNA Binding Vesicant Extravasation. Answer: -Vinca
Alkaloids (vincristine, vinblastine)
-Do not bind to DNA in healthy cells when they extravasate into tissue.
Indirect effect on healthy tissue
-Treat with heat, elevation, and hyaluronidase local injection (spreads the
vesicant through the tissue for faster metabolism of the vesicant agent)
-Usually results in less tissue damage
-Improves over a short period of time (days to weeks(
▶ Management of DNA-Binding Vesicant Extravasation. Answer: --
Anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin)
-Binds to DNA in healthy cells when they extravasate into tissue
-When not immediately treated with dexrazoxane, the vesicant remains in
the tissue and invades adjacent healthy tissue
, -Likely to result in more tissue damage
-Left untreated, extravasations become larger and deeper, worsening over
time (weeks to months)
▶ Lesson 11: Targeted Therapy. Answer:
▶ How targeted therapy and chemo differ. Answer: -targeted therapies act
on specific molecular targets on or within the cells that are associated with
cancer, whereas standard chemo act on all rapidly dividing cells
-chemo has more SEs
-targeted therapy ae chosen and designed to interact with their target on or
within the cells, whereas chemo were IDed becaused they kill cells
-targeted therapies are often cytostatic (they block tumor cell proliferation)
whereas chemo agents are cytotoxic (kill tumor cells)
▶ Goals of targeted therapy. Answer: -disease cure when used as primary
or adjuvant therapy
-improving overall response or increase disease-free survival when used in
combination with conventional therapies
QUESTIONS WITH ACCURATE SOLUTIONS
2026
▶ Managing Non-DNA Binding Vesicant Extravasation. Answer: -Vinca
Alkaloids (vincristine, vinblastine)
-Do not bind to DNA in healthy cells when they extravasate into tissue.
Indirect effect on healthy tissue
-Treat with heat, elevation, and hyaluronidase local injection (spreads the
vesicant through the tissue for faster metabolism of the vesicant agent)
-Usually results in less tissue damage
-Improves over a short period of time (days to weeks(
▶ Management of DNA-Binding Vesicant Extravasation. Answer: --
Anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin)
-Binds to DNA in healthy cells when they extravasate into tissue
-When not immediately treated with dexrazoxane, the vesicant remains in
the tissue and invades adjacent healthy tissue
, -Likely to result in more tissue damage
-Left untreated, extravasations become larger and deeper, worsening over
time (weeks to months)
▶ Lesson 11: Targeted Therapy. Answer:
▶ How targeted therapy and chemo differ. Answer: -targeted therapies act
on specific molecular targets on or within the cells that are associated with
cancer, whereas standard chemo act on all rapidly dividing cells
-chemo has more SEs
-targeted therapy ae chosen and designed to interact with their target on or
within the cells, whereas chemo were IDed becaused they kill cells
-targeted therapies are often cytostatic (they block tumor cell proliferation)
whereas chemo agents are cytotoxic (kill tumor cells)
▶ Goals of targeted therapy. Answer: -disease cure when used as primary
or adjuvant therapy
-improving overall response or increase disease-free survival when used in
combination with conventional therapies
